Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.80 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.69 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.62 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.61 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1217683 | 1.00 | CYP1A2 (0.80) | CYP1A2FFAR1PDPK1KEAP1FFAR4 | |
| Hydrochloric Acid SCHEMBL27401796 | 0.98 | CYP1A2 (0.77) | CYP1A2FFAR1PDPK1KEAP1FFAR4 | |
| SCHEMBL5593881 | 0.94 | CYP1A2 (0.72) | CYP1A2FFAR1PDPK1KEAP1FFAR4 | |
| SCHEMBL9670503 | 0.92 | CYP1A2 (0.67) | CYP1A2FFAR1PDPK1KEAP1FFAR4 | |
| Trifluoroacetic Acid SCHEMBL27484822 | 0.92 | CYP1A2 (0.69) | CYP1A2FFAR1PDPK1KEAP1FFAR4 | |
| SCHEMBL30061865 | 0.89 | CYP1A2 (1.00) | CYP1A2FFAR1PDPK1CYP2D6CYP2C19 | |
| SCHEMBL2318140 | 0.89 | CYP1A2 (1.00) | CYP1A2FFAR1PDPK1CYP2D6CYP2C19 | |
| SCHEMBL5638276 | 0.87 | CYP1A2 (0.90) | CYP1A2FFAR1PDPK1CYP2D6CYP2C19 | |
| SCHEMBL7332873 | 0.86 | CYP1A2 (0.66) | CYP1A2FFAR1PDPK1CYP2D6CYP2C19 | |
| SCHEMBL10439522 | 0.86 | CYP1A2 (0.87) | CYP1A2FFAR1PDPK1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036772-A | Synthesis method of beta-pinacol borate-alkyl ketone compound | 陇东学院 | 2026-05-15 | — | — | CN | claimed |
| CN-122036772-A | Synthesis method of beta-pinacol borate-alkyl ketone compound | 陇东学院 | 2026-05-15 | — | — | CN | disclosed |
| EP-4698229-A1 | BISPECIFIC CYTOTOXICITY TARGETING CHIMERAS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2026-02-25 | — | — | EP | disclosed |
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-25 | — | — | US | disclosed |
| CN-120157577-A | Application of tetra-n-butyl ammonium bromide as catalyst in catalyzing reaction of methoxyl aromatic hydrocarbon and acyl bromide | 皖南医学院 | 2025-06-17 | — | — | CN | disclosed |
| WO-2024218361-A1 | BISPECIFIC CYTOTOXICITY TARGETING CHIMERAS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024140687-A1 | S1PR2 REGULATOR AND USE THEREOF | 北京昌平实验室 | 2024-07-04 | — | — | WO | disclosed |
| CN-118255830-A | S1PR2 modulators and uses thereof | 北京昌平实验室 | 2024-06-28 | — | — | CN | disclosed |
| CN-116194155-A | Urea-based ligands targeting PSMA for prostate cancer radiotherapy and imaging | 哥本哈根大学 | 2023-05-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | GIPR, VIP, GRPR | CYP1A2 4178/4885FFAR1 161/4885PDPK1 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.